13.2 Enter all patients by phoning Dr. Heslop or Dr. Brenner. The following forms 
should be completed: 
On study form 
Investigational agents flow sheet forms 
Off study forms 
13.3 Adverse reactions will be reported by phone to Dr. Heslop or Dr. Brenner 
within 24 hours of their occurrence. These adverse reaction reports include all 
life-threatening events (Grade 3/4 toxicity, Section 9.0) which may be due to 
tumor cell injection, and all fatal events. 
14.0 INFORMED CONSENT 
All patents and/or their legal guardian must sign a document of informed consent 
consistent with local institutional and Federal guidelines stating that they are aware 
of the investigational nature of this protocol and of the possible side effects of 
treatment. Further, patients must be informed that no efficacy of this therapy is 
guaranteed, and that unforeseen toxicities may occur. Patients have the right to 
withdraw from this protocol at any time. No patient will be accepted for treatment 
without such a document signed by him or his legal guardian. Full confidentiality of 
patients and patient records will be provided according to institutional guidelines. 
15.0 REFERENCES 
1. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, 
Clift R, Doney K, Martin PJ, Mickelson E, Nisperos B, O'Quigley J, Ramberg 
R, Sanders JE, Stewart P, Storb R, Sullivan KM, Witherspoon RP, Thomas ED, 
Hansen JA. Effect of HLA compatibility on engraftment of bone marrow 
transplants in patients with leukemia or lymphoma. N Engl J Med 320:197-204, 
1989. 
2. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, 
Sanders JE, Stewart P, Buckner CD, Storb R, Thomas ED, Hansen JA. Marrow 
transplantation from related donors other than HLA-identical siblings. N Engl 
J Med 313:765-771,1985. 
3. Gajewski, Cecka M, Champlin R. Bone marrow transplantation utilizing HLA- 
matched unrelated marrow donors. Blood Rev 4.132-138,1990. 
Recombinant DNA Research, Volume 17 
[213] 
